Quest Partners LLC Has $38,000 Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Quest Partners LLC lowered its stake in Omnicell, Inc. (NASDAQ:OMCL) by 71.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 877 shares of the company’s stock after selling 2,217 shares during the period. Quest Partners LLC’s holdings in Omnicell were worth $38,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of OMCL. Nisa Investment Advisors LLC boosted its holdings in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after acquiring an additional 1,000 shares during the period. GAMMA Investing LLC lifted its holdings in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the last quarter. CWM LLC boosted its stake in Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the period. 1620 Investment Advisors Inc. grew its holdings in Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in Omnicell during the 2nd quarter worth $104,000. 97.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on OMCL shares. Craig Hallum boosted their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Barclays lifted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. increased their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Wells Fargo & Company raised their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Finally, StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Omnicell presently has a consensus rating of “Hold” and an average price target of $52.00.

Omnicell Stock Down 3.9 %

Shares of Omnicell stock opened at $46.59 on Friday. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.74. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -119.46, a PEG ratio of 36.82 and a beta of 0.81. The firm’s 50-day moving average price is $44.55 and its two-hundred day moving average price is $37.99.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.